Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use

Authors

  • Piero Impicciatore,

    1. Academic Division of Child Health, (University of Nottingham), Derbyshire Children’s Hospital, Derby, UK,
    2. Laboratory for Mother and Child Health, Istituto di Ricerche Farmacologiche Mario Negri’, Milano, Italy
    Search for more papers by this author
  • Imti Choonara

    1. Academic Division of Child Health, (University of Nottingham), Derbyshire Children’s Hospital, Derby, UK,
    Search for more papers by this author

Professor Imti Choonara Derbyshire Children’s Hospital, Uttoxeter Road, Derby DE22 3NE, UK.

Abstract

Aims To evaluate the activity of the European Medicines Evaluation Agency with regard to the registration for paediatric use of new medicines granted a marketing authorization.

Methods European Public Assessment Reports published on the Internet from January 95 until April 98 have been analysed using the browser Microsoft Explorer and the software Adobe Acrobat Reader.

Results Of the 45 new substances licensed since January 95, 29 (64%) were of possible use in children but only 10 were licensed for paediatric use. For the 19 drugs of possible use in children, but not approved for such a use, in nine instances (47%) their summary of product characteristics reported that their use in children has not been established.

Conclusions A change of practice by pharmaceutical companies and regulatory authorities is imperative so that children are not precluded from having the same rights to medicines as adults.

Ancillary